The following FAQs highlight key recommendations and practical takeaways from the 2026 AUA/SUO Advanced Prostate Cancer Guideline. Two overarching themes define the 2026 amendment: the consolidation ...
Atish D. Choudhury, MD, PhD, discusses findings from the A-DREAM / Alliance A032101 trial evaluating treatment interruption following favorable response to combination ADT and ARPI therapy in mHSPC.
Tentative FDA approval enables Lupin to prepare for commercial launch of generic enzalutamide once remaining exclusivity and patent constraints no longer block approval. Bioequivalence was established ...
CONVERGE-01 enrolled progressive PSMA-positive mCRPC after 1–6 prior Lu-177–PSMA cycles, with universal ARPI exposure and 80% prior taxane use in the ASCO cohort. Fractionated CONV01-α on days 1 and ...
The approval is supported by data from the phase 3 PIVOT-PO trial, in which tebipenem demonstrated noninferiority to imipenem-cilastatin. This decision marks the first approval of an oral carbapenem ...
Labeling would drop the limitation of use for age-related hypogonadism, reflecting an evidence reassessment that no longer supports language implying unestablished safety and effectiveness in this ...
OAB is a chronic, potentially debilitating condition affecting a substantial proportion of patients in urologic practice, and effective long-term management depends on systematic escalation from ...
The approval is supported by data from the phase 3 CAPItello-281 trial. On June 12, 2026, the FDA approved capivasertib (Truqap) in combination with abiraterone acetate (Zytiga) and prednisone for ...
Live Events | Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results